What antihypertensive medications are safe to use in a 21‑year‑old woman with lupus nephritis, elevated creatinine, posterior reversible encephalopathy syndrome (PRES) and seizures after nitroglycerin (NTG) infusion is tapered and stopped, with blood pressure 150/100 mmHg and pulse 105 bpm?

Safe Antihypertensive Agents for Lupus Nephritis with Elevated Creatinine, PRES, and Seizures

For this 21-year-old woman with lupus nephritis, elevated creatinine, PRES, and seizures after NTG taper, you should use ACE inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) as first-line agents, combined with calcium channel blockers (CCBs) for additional blood pressure control, while avoiding very high-dose corticosteroids which are associated with increased PRES risk and mortality.

Primary Antihypertensive Strategy

First-Line: RAAS Blockade

• ACEIs or ARBs are the preferred agents for lupus nephritis with hypertension 1, 2
• These agents provide both blood pressure control AND renoprotection through reduction of proteinuria 3
• The KDIGO 2024 guidelines explicitly recommend renin-angiotensin system blockade for blood pressure control in lupus nephritis patients 1
• Despite elevated creatinine, RAAS blockade remains appropriate and beneficial—one case report demonstrated successful use of losartan in a patient with severe AKI and PRES, resulting in improvement in both blood pressure and creatinine 4

Practical dosing approach:

• Start with low doses given the elevated creatinine (e.g., lisinopril 5-10 mg daily or losartan 25-50 mg daily)
• Monitor creatinine closely—expect a modest rise (up to 30%) which is acceptable
• Titrate upward as tolerated to achieve target BP <130/80 mmHg 2

Second-Line: Calcium Channel Blockers

• Add a CCB for additional blood pressure control if RAAS blockade alone is insufficient 4, 5
• Non-dihydropyridines (diltiazem, verapamil) should be avoided given her tachycardia (PR 105)
• Use dihydropyridines instead: amlodipine 5-10 mg daily or nifedipine extended-release 30-60 mg daily

Additional Considerations

Aldosterone Antagonists

• Spironolactone can be added for resistant hypertension and additional antiproteinuric effects 4
• Use cautiously with elevated creatinine—monitor potassium closely
• Typical dose: 25-50 mg daily

Blood Pressure Targets

• Target BP should be <130/80 mmHg in this patient with lupus nephritis 2
• Hypertension is a major risk factor for PRES in SLE patients—all patients in the literature had hypertension at PRES onset 5, 6, 7
• Strict blood pressure control is essential to prevent PRES recurrence 5, 8

Critical Safety Considerations

Avoid Very High-Dose Corticosteroids

• Very high-dose glucocorticoids are independently associated with PRES development (OR 14.352) and significantly increased mortality (50% vs 88-100% survival with lower doses) 7
• If immunosuppression is needed for active lupus nephritis, use moderate-dose corticosteroids combined with other agents (mycophenolate, cyclophosphamide, or voclosporin) per KDIGO guidelines 1

Monitor for Hypomagnesemia

• Hypomagnesemia is a newly identified risk factor for PRES in SLE (OR 8.360) 7
• Check and correct magnesium levels—this patient is at high risk given nephritis and likely diuretic use
• Target magnesium >2.0 mg/dL

Seizure Management

• Continue antiepileptic therapy as initiated 5, 6
• PRES-related seizures typically resolve with blood pressure control and do not require long-term anticonvulsants, but continue for at least 3-6 months given the severity

Agents to Avoid

Do NOT use:

• Beta-blockers as monotherapy—will worsen her tachycardia management but won't address the underlying endothelial dysfunction
• Direct vasodilators (hydralazine, minoxidil)—can cause reflex tachycardia and are less effective for renoprotection
• Very high-dose corticosteroids (>1 mg/kg/day prednisone equivalent)—associated with PRES and increased mortality 7

Monitoring Plan

• Daily blood pressure monitoring until stable <130/80 mmHg
• Creatinine and potassium within 5-7 days of starting RAAS blockade, then weekly until stable
• Magnesium levels weekly initially
• Proteinuria (urine protein-to-creatinine ratio) at 2-4 weeks to assess antiproteinuric response
• Clinical neurological assessment daily—watch for recurrent visual changes, headache, or seizures

Pathophysiologic Rationale

This patient's PRES occurred in the context of multiple risk factors: hypertension, active lupus nephritis, and likely immunosuppressive therapy 7, 9. The endothelium is critically compromised by lupus vasculopathy, hypertension, and possibly hypoalbuminemia from nephrotic syndrome 9. RAAS blockade addresses the fundamental pathophysiology by reducing both systemic blood pressure and intraglomerular pressure while stabilizing endothelial function 1, 4, 2.

The tachycardia (PR 105) likely represents compensatory response to hypertension and should improve with blood pressure control rather than requiring direct rate control initially.